Moderna enrolls Phase 2 trial to test mRNA-1647 immunogenicity & safety
Category: #health  By Pankaj Singh  Date: 2020-02-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Moderna enrolls Phase 2 trial to test mRNA-1647 immunogenicity & safety

Moderna, Inc., a biotechnology company pioneering in drug discovery and development based on mRNA, has recently announced the enrollment of the Phase 2 dose-confirmation study. The data for the clinical study of mRNA vaccine against CMV (cytomegalovirus), which is enrolling ahead of plan, is expected in the Q3 of 2020, with the near completion of the second cohort.

The Phase 2 study was designed to investigate the immunogenicity and safety of mRNA-1647 in around 252 healthy adults in the United States. The study was evaluated at 3 dose levels (50, 100, & 150 μg) and 3 vaccination schedules (0, 2, & 6 months) among CMV-seropositive and CMV-seronegative participants. The company is actively working on a Phase 3 pivotal study which will focus on evaluating the best prevention against cytomegalovirus in a population of women of childbearing age.

Moderna also undertaking strategic measures to accelerate new development candidates in its prophylactic vaccines, systemic secreted and cell surface therapeutics, and core modalities. The company has recently announced three new infectious disease candidates for accelerated vaccine development, namely mRNA-1189 against Epstein-Barr virus, mRNA-1345 against respiratory syncytial virus, and mRNA-1273 against novel coronavirus. The three new vaccine candidates also complement the company’s recent announcement of delivering IL-2 (mRNA-6981) and PD-L1 (mRNA-6231), which are autoimmune development candidates. These candidates are developed by utilizing Moderna’s proprietary LNP (lipid nanoparticle) technology.

The company currently has over 24 mRNA development candidates in its portfolio, with 12 candidates enrolled in clinal studies. Nearly 1,500 candidates have been enrolled for the clinical studies across Moderna’s pipeline. Its proprietary vaccine technology leverages flexible manufacturing infrastructure and digital systems.

According to CEO of Moderna, Stéphane Bancel, the company’s recent investments have resulted in 6 positive Phase 1 vaccine readouts for infectious diseases. This in turn has led to the acceleration and advancement in R&D timelines of mRNA vaccines, which reflects the potential of the mRNA technology. Mr. Bancel also expressed his anticipation about the company’s response to the ongoing coronavirus epidemic by introducing innovative solutions like the mRNA-1273.

Source credit:

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-progress-prophylactic-vaccines-modality-cmv



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Greenphire introduces new budget tool to streamline clinical trails
Greenphire introduces new budget tool to streamline clinical trails
By Pankaj Singh

Greenphire Inc, one of the world’s leading companies in financial lifecycle management for clinical trials, has reportedly launched a new budget development solution named EnvisiX to address the budgeting challen...

Gilead’s Remdesivir improves clinical outcomes in COVID-19 patients
Gilead’s Remdesivir improves clinical outcomes in COVID-19 patients
By Pankaj Singh

The novel coronavirus outbreak, which led to the on-going COVID-19 pandemic, has affected over five million people and taken the lives of over 300 thousand worldwide. But unfortunately, researchers have not been able t...

WHO halts Hydroxychloroquine clinical trial over safety concerns
WHO halts Hydroxychloroquine clinical trial over safety concerns
By Pankaj Singh

The malaria drug Hydroxychloroquine has been in the headlines for the past few months. The drug was hailed as the game-changer in the treatment of COVID-19 by the Trump administration. However, the WHO (World Health Or...